Body Composition in Anti-Obesity Medication Trials-Beyond Scales.

Agarwal, Ank A; Narayan, Aditya; Stanford, Fatima Cody

Agarwal, Ank A; Narayan, Aditya; Stanford, Fatima Cody.

Afiliación

Agarwal AA; Stanford University School of Medicine, Palo Alto, California.
Narayan A; Stanford University School of Medicine, Palo Alto, California.
Stanford FC; Neuroendocrine Unit, Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston.

JAMA Intern Med ; 184(4): 341-342, 2024 Apr 01.

Article en En | MEDLINE | ID: mdl-38372971

This Viewpoint contends that focusing only on weight loss as the primary weight medication end point is an inaccurate measure of medication efficacy for both patients and clinicians.

Asunto(s)

Fármacos Antiobesidad; Humanos; Fármacos Antiobesidad/uso terapéutico; Pérdida de Peso; Composición Corporal

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fármacos Antiobesidad Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fármacos Antiobesidad Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article